The independent medical news service

Incorporating a drug-free interval into first-line treatment for metastatic clear cell renal cell carcinoma may not be detrimental to patient survival or quality of life, suggest STAR trial data presented at the ESMO Congress 2021.

Read more on this US FDA announcement here

Click through for the details of this decision

A patient-derived tumor fragment platform has allowed close examination of the early immunologic responses to PD-1 blockade, revealing a relationship between immune cell reactivation and clinical response.

Preliminary research presented at the 2021 ASCO Annual Meeting suggests that use of a bacterial product might improve response to checkpoint inhibitor therapy in patients with metastatic renal cell carcinoma.

Patients who receive lenvatinib plus pembrolizumab for advanced renal cell carcinoma report similar or better health-related quality of life than those who receive sunitinib, show data from the phase 3 CLEAR trial.

The combination of telaglenastat and cabozantinib offers no extra benefit over cabozantinib alone in the second- or third-line treatment of advanced clear cell renal cell carcinoma, suggest phase 2 trial results.

Postoperative treatment with pembrolizumab significantly improves the disease-free survival of patients with high-risk, clear cell renal cell carcinoma relative to placebo, show trial data.

Real-world study data show that first-line immunotherapy alone or in combination with targeted therapy is associated with better overall survival than targeted therapy alone in people with metastatic clear cell renal cell carcinoma.

Previously untreated patients with advanced non-clear cell renal cell carcinoma could benefit from treatment with lenvatinib plus everolimus, suggests a phase 2 study.

Individuals with obesity tend to have worse cancer survival outcomes than those without obesity, unless they have lung cancer, renal cell carcinoma, or melanoma, show findings of a systematic review and meta-analysis.

Real-world data suggest that active surveillance may be a feasible treatment option for some patients with metastatic renal cell carcinoma.

More information about this approval here

Researchers report an association between high BMI and improved outcomes in response to immune checkpoint inhibitors in patients with metastatic renal cell carcinoma.

Click through to read more

Combination therapy with the HIF-2α inhibitor belzutifan and the multikinase inhibitor cabozantinib shows antitumor activity in people with metastatic clear cell renal cell carcinoma, phase 2 study data show.

The CLEAR study has demonstrated a significant progression-free survival gain with use of lenvatinib plus pembrolizumab for the first-line treatment of advanced clear cell renal cell carcinoma.

A number of baseline variables, including age and PD-L1 expression level, may be linked to survival outcomes among people receiving PD-1 or PD-L1 inhibitors for metastatic clear cell renal cell carcinoma, meta-analysis data show.

Read more about this here

Read more about these decisions here